Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Thursday 01 July, 2021

Ergomed plc

Block listing Interim Review

RNS Number : 7034D
Ergomed plc
01 July 2021
 

 

 

Block Listing Application and Block Listing Return

 

 

Block Listing Application

 

Guildford, UK - 1 July 2021 : An application has been made to the London Stock Exchange for a block admission of securities in respect of 600,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.

 

It is expected that the admission of the New Ordinary Shares will become effective on 7 July 2021 and will be reflected as an increase from that point on the Company's next Block Listing Return.

 

New Ordinary Shares admitted under the Company's Block Listing will be allotted from time to time in accordance with the exercise of options under the Ergomed plc Long Term Incentive Plan.

 

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the Company's existing ordinary shares of £0.01 each.

 

The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Block Listing Six Monthly Return

 

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

1 January 2021

To:

30 June 2021

Balance of unallotted securities under scheme(s) from previous return:

1,565,722

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

99,322

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,466,400

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

1,500,000 ordinary shares of 1p each - 31 December 2019

Total number of securities in issue at the end of the period

48,818,848 ordinary shares of 1p each

 

Name of contact:

Nick Roberts - Head of Group Reporting

Telephone number of contact:

+44 (0) 1483 503 205

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal 

[email protected]

Angela Gray / Lucy Featherstone




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:  http://ergomedplc.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREALKEDEFFEFA

a d v e r t i s e m e n t